In so doing, it attempts to contribute to (1) an understanding of the establishment and structure of the mAb innovation system in China; (2) an evaluation of the performance of the mAb development system by analysing the functions of the development system; and (3) providing policy suggestions for improving the mAb development system. Further, this paper offers an overview of the functions of development system approach, which provided the theoretical framework for examining the mAb development system, and analyses the development system of mAbs and the function fulfilment. being driven by incentives such as the subsidies from your State and corporate R&D funding. Knowledge diffusion has been well served over the last 10 years through exchanging information on networks and technology transfer with developed countries. The State has provided obvious LDC1267 guidance on search of emerging mAb technologies. Legitimacy of mAb in China has gained momentum owing to the implementation of government guidelines stipulated in the The Eleventh Five-year Plan in 2007, as well as national projects such as the 973 Program and 863 Program, among others. The potential of market formation stays high because of the rising local demand and government support. Entrepreneurial activities for mAb continue to prosper. In addition, the situation of resource supply has been improved with the support of the State. Conclusions This study finds that a total development system for mAb has begun to take shape in China. MAb innovators in China are capitalizing on this emerging technological opportunity to participate in the global LDC1267 drive of developing the value chain for the innovative drug. In the long run, the build-up of LDC1267 the research system for mAb in China could produce more driving causes to the mAb development system. strong class=”kwd-title” Keywords: China, Emerging technology, Innovation system, Monoclonal antibody Background Over the past three decades, monoclonal antibodies (mAbs) have made a dramatic transformation from scientific tools to powerful human therapeutic brokers [1]. Sales of mAb therapies exceeded 40 billion US dollars in 2010 2010 and are expected to reach 70 billion US dollars by 2015 [2]. In 1975, Koehler and Milstein first explained the in vitro production of murine mAbs from hybridomas [3]. In the late 1980s, clinical development of murine mAbs was initiated but then inhibited by numerous significant drawbacks [4]. Later, in an attempt to overcome the inherent immunogenicity concerns and the reduced effect or function of murine mAbs in human [5], chimeric mouse-human antibodies were developed [6]. Nowadays, humanized mAbs are the fastest growing category of mAb therapeutics entering clinical study [7]. Development of this class of therapeutic agents started as early as 1980s but achieved no clinical or commercial success until 2002, when adalimumab became the first humanized mAb approved by the United States Food and Drug Administration [8]. Thus far, a total of seven humanized mAbs have been approved for marketing in the United States. While mAbs, as an emerging technology, have become progressively important in the development of human therapeutic brokers, how developing countries such as China could seize this emerging technological opportunity remains a scantly analyzed topic in prior literature. Aiming at investigating mAb development in China by drawing on an development systems approach, this paper probes into the question of how China has been taking advantage of emerging technologies to overcome difficulties through building up an development system in developing mAbs. In so doing, it attempts to contribute to (1) an understanding of the establishment and structure of MDK the mAb development system in China; (2) an evaluation of the performance of the mAb development system by analysing the functions of the development system; and (3) providing policy suggestions for improving the LDC1267 mAb development system. Further,.
In so doing, it attempts to contribute to (1) an understanding of the establishment and structure of the mAb innovation system in China; (2) an evaluation of the performance of the mAb development system by analysing the functions of the development system; and (3) providing policy suggestions for improving the mAb development system
